N
Niall M. Heney
Researcher at Harvard University
Publications - 115
Citations - 8082
Niall M. Heney is an academic researcher from Harvard University. The author has contributed to research in topics: Bladder cancer & Cystectomy. The author has an hindex of 42, co-authored 113 publications receiving 7573 citations. Previous affiliations of Niall M. Heney include Brigham and Women's Hospital & University of Maryland, Baltimore.
Papers
More filters
Journal ArticleDOI
Superficial Bladder Cancer: Progression and Recurrence
Niall M. Heney,Susan W. Ahmed,Malachi J. Flanagan,William J. Frable,Michael P. Corder,Mark D. Hafermann,Ileana R. Hawkins,George R. Prout,G.H. Friedell,David A. Culp,Stefan A. Loening,K.B. Cummings,S.J. Cutler,M.J. Flanagan,Warren W. Koontz,Harper M. Pearse,C. Merrin,Z. Wajsman,Clair E. Cox,Mark S. Soloway +19 more
TL;DR: High tumor grade, lamina propria invasion, atypia elsewhere in the bladder, positive urinary cytology, tumor multiplicity and large tumors were associated with shorter intervals free of disease and correlated with nontumor dysplasia and size.
Journal ArticleDOI
Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer
William U. Shipley,W. Seiferheld,H. Lukka,Pierre Major,Niall M. Heney,David J. Grignon,Oliver Sartor,Maltibehn P. Patel,Jean Paul Bahary,Anthony L. Zietman,Thomas M. Pisansky,Kenneth L. Zeitzer,Colleen A. Lawton,Felix Y. Feng,Richard Dana Lovett,Alexander Balogh,Luis Souhami,Seth A. Rosenthal,Kevin J. Kerlin,James J. Dignam,Stephanie L. Pugh,Howard M. Sandler +21 more
TL;DR: The addition of 24 months of antiandrogen therapy with daily bicalutamide to salvage radiation therapy resulted in significantly higher rates of long‐term overall survival and lower incidences of metastatic prostate cancer and death from prostate cancer than radiation therapy plus placebo.
Journal ArticleDOI
Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03.
William U. Shipley,K.A. Winter,Donald S. Kaufman,W.R. Lee,Niall M. Heney,W.R. Tester,B.J. Donnelly,P.M. Venner,Carlos A. Perez,K.J. Murray,R.L.S. Doggett,L.D. True +11 more
TL;DR: To assess the efficacy of neoadjuvant methotrexate, cisplatin, and vinblastine (MCV) chemotherapy in patients with muscle-invading bladder cancer treated with selective bladder preservation, clinical stage T2 to T4aNXMO bladder cancer was treated.
Journal ArticleDOI
Advanced prostate cancer: The results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone
William U. Shipley,Lynn Verhey,John E. Munzenrider,Herman D. Suit,Marcia Urie,P.L. McManus,Robert H. Young,Jenot W. Shipley,Anthony L. Zietman,Peter J. Biggs,Niall M. Heney,Michael Goitein +11 more
TL;DR: An increase in prostate tumor dose by external beam of 12.5% to 75.6 Cobalt Gray Equivalent using a conformal perineal proton boost significantly improved local control only in patients with poorly differentiated tumors.
Journal ArticleDOI
Long-Term Outcomes of Selective Bladder Preservation by Combined-Modality Therapy for Invasive Bladder Cancer: The MGH Experience
Jason A. Efstathiou,Daphna Y. Spiegel,William U. Shipley,Niall M. Heney,Donald S. Kaufman,Andrzej Niemierko,John J. Coen,Rafi Y. Skowronski,Jonathan J. Paly,Francis J. McGovern,Anthony L. Zietman +10 more
TL;DR: CMT achieves a CR and preserves the native bladder in >70% of patients while offering long-term survival rates comparable to contemporary cystectomy series, which support modern bladder-sparing therapy as a proven alternative for selected patients.